The BCMA / NF-kappaB - HEK293 recombinant cell line has been transfected with full-length human BCMA cDNA (Genbank #NM_001192) under control of a CMV promoter for high constitutive expression. The NF-kappaB-luciferase reporter is also stably integrated into the genome. The firefly luciferase gene is controlled by four copies of the NF-kappaB Response Element upstream of a minimal promoter. Upon ligand binding, active BCMA will initiate the NF-kappaB signaling pathway, leading to expression of the NF-kappaB-controlled luciferase reporter.
Mycoplasma testing: This cell line has been screened using the Venor GeM Mycoplasma Detection Kit, PCR Based (Sigma, #MP0025) to confirm the absence of Mycoplasma contamination.
Host Species: human
Supplied as Two vials containing ~ 2 x 106 cells in 1 ml of 10% DMSO in FBS
Background
B-Cell Maturation Antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269, is a type I membrane protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily, that recognizes its ligands including BAFF (B-cell activating factor) and APRIL (a proliferation inducing ligand). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. In vitro, the activation of BCMA by its ligand promotes the differentiation and proliferation of B cells. A vast array of intracellular activity is involved in BCMA-induced signal transduction, including activation of the NF-kappaB signaling pathway. The bioactivity of BAFF and APRIL as soluble homotrimers distinguishes them from other TNFSF ligands such as TRAIL, FasL, and CD40L, which are only active as membrane-bound molecules.
License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid multiple freeze/thaw cycles.
Storage Stability
Store in liquid nitrogen immediately upon receipt. Do not store long-term at -80°C or on dry ice.
Reference
Hahne, M. et al. (1998) J. Exp. Med. 188:1185. Yu, G. et al. (2000) Nat. Immunol. 1:252. Yan, M. et al. (2000) Nat. Immunol. 1:37. Gravestein, L.A. and Borst, J. (1998) Sem. Immunol. 10:423.